Original Article

Diarrhea-Predominant Irritable Bowel Syndrome: Medical Management Update

Christopher N. Andrews, MD 1, Marc Bradette, MD 2

1Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada; 2Division of Gastroenterology, Centre Hospitalier Universitaire de Québec (CHU), Laval University, Québec, Québec, Canada

Correspondence: Christopher N. Andrews, MD, Division of Gastroenterology, University of Calgary, TRW Building 6D34 3280 Hospital Drive NW, Calgary, Alberta, T2N 4Z6, Canada, e-mail: candrews@ucalgary.ca

Abstract

Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder, which impacts the quality of life, work productivity and social activities of patients. Diarrhea-predominant IBS (IBS-D) is one of several subtypes, and accounts for approximately one third of all cases. Currently available treatments are typically unable to alleviate the cardinal symptoms of IBS-D, including abdominal pain and diarrhea, and a clinical unmet need remains for an effective treatment which simultaneously relieves multiple symptoms. Patients may benefit from a multipronged, individualized approach, including dietary modifications, and psychological and pharmacological therapies. The aim of this review is to provide an update on the available and upcoming treatment options for IBS-D in Canada, with reference to the recently updated Canadian IBS consensus guidelines. Initial treatment approaches include lifestyle modifications, dietary modifications, and non-prescription therapies such as peppermint oil. While some medications such as tricyclic antidepressants are also used to treat IBS-D symptoms, eluxadoline and rifaximin are the only two pharmacological therapies approved for the treatment of IBS-D in Canada. Key clinical trial data for the currently available pharmacological options are presented to provide an overview of the efficacy and safety of these agents.

Keywords: Diarrhea-predominant irritable bowel syndrome; Management; Treatment

Irritable Bowel Syndrome Background

Irritable bowel syndrome (IBS) is a common disorder, affecting approximately 11% of the global population (1). It is estimated that approximately five million Canadians may have IBS (2), or 10 to 14% of the population (3). This functional bowel disorder is defined by the presence of recurrent abdominal pain associated with defecation or a change in bowel habits (4). A positive diagnosis of IBS is made based on symptom history using Rome IV criteria (5), with minimal need for diagnostic testing (4). Based on these criteria, patients with IBS can be grouped into one of four subtypes: constipation-predominant IBS, diarrhea-predominant IBS (IBS-D), mixed IBS, where the stool patterns vary from constipation to diarrhea, or unclassified IBS (5). IBS-D accounts for approximately one third of all cases (3).

In addition to the cardinal symptoms of IBS-D, including diarrhea and abdominal pain, there are numerous other symptoms including fecal urgency and bloating (4,6–8).

Patients with IBS report significant impact on their work productivity, time management, and participation in social activities due to their symptoms (9). One study found that individuals with IBS in Canada missed the equivalent of 13.8 hours per 40-hour work week due to presenteeism or absenteeism (10). IBS is also associated with comorbid conditions such as anxiety, stress and depression (11), with one study in Canada reporting that 34% of patients with IBS also had comorbid anxiety disorders (12).

The pathogenesis of IBS is thought to be multifactorial, involving visceral hypersensitivity, abnormal gut motility, and...
with a control diet (risk ratio [RR]: 0.69; 95% confidence interval [CI]: 0.54 to 0.88) (23). However, due to the fact that the details of a low-FODMAP diet are readily available on the internet, most of these trials were classified as not blinded (23). In the two studies considered to have adequate levels of blinding, which included 167 patients, the low-FODMAP diet showed no benefit versus an alternative diet (RR: 0.89; 95% CI: 0.68 to 1.17; \( P = 0.84 \)) (19,23–25).

In combination with the low number of participants and heterogeneity in the study design, these factors led to the efficacy of a low-FODMAP diet being designated as having a ‘low quality of evidence’ (23). In addition, a low-FODMAP diet is highly restrictive, and the ability of patients to adhere to such a diet has been shown to impact its effectiveness (20).

### Existing Therapies

#### Psychological Therapies

IBS-D is associated with a high disease burden and low quality of life, which psychological interventions may help to address (26). Referral to psychological treatment may be recommended as part of a multidisciplinary approach to managing IBS symptoms (26). Evidence suggests that psychological therapies, particularly cognitive behavioural therapy and hypnotherapy, can be effective in the management of IBS symptoms. For instance, in a meta-analysis of 15 randomized controlled studies of 1352 patients, psychological therapies (such as cognitive behavioural therapy and stress management) were associated with improvement in IBS symptom severity scales (standardized mean difference [SMD]: \(-0.618\); 95% CI: \(-0.853\) to \(-0.383\)), IBS – Quality of Life questionnaire scores (SMD: 0.604; 95% CI: 0.440 to 0.768), and abdominal pain scales compared with controls (SMD: \(-0.282\); 95% CI: \(-0.562\) to \(-0.001\)) (27). The CAG has suggested that psychological therapies are a management option, although accessibility to treatment may present challenges for patients (19).

#### Nonprescription Therapies

Nonprescription therapies for the treatment of IBS-D include loperamide, probiotics and peppermint oil. Loperamide is a synthetic peripheral \(\mu\)-opioid receptor agonist that reduces colonic transit, urgency, and stool consistency in IBS patients (4). In a prospective, double-blind study of patients with IBS (\(n = 69\)), loperamide was shown to improve stool consistency (by 32%), reduce defecation frequency (by 36%) and reduce the intensity of pain (by 30%) throughout the 5-week study period (28). However, the overall quality of evidence for the use of loperamide in treating IBS has been reported as ‘very low’ by the American College of Gastroenterology (ACG) (29,30). ACG guidelines also suggest that although loperamide is an effective antidiarrheal, there is insufficient evidence to recommend it for the relief of global IBS symptoms (29,30). Similarly, CAG guidelines suggest against offering continuous loperamide to patients with IBS-D (19).
Probiotics are live micro-organisms that can provide health benefits. Across studies, probiotics appear effective in reducing global IBS symptom scores or abdominal pain scores, bloating scores, and flatulence scores (30,31), although the quality of evidence for their use is also considered ‘low’ by the ACG and CAG, particularly due to significant heterogeneity between studies and the use of different probiotics across studies (19,30).

Peppermint oil is a relatively low-cost intervention which has demonstrated consistently favourable results in improving IBS symptoms, and CAG guidelines conditionally suggest offering peppermint oil as a treatment option (19).

**Off-Label Prescription Therapies**

A number of prescription therapies are used off-label for the treatment of IBS-D, including bile acid sequestrants and tricyclic antidepressants (21). Bile acid diarrhea may occur in up to one third of patients with IBS-D, and bile acid sequestrants have been reported to improve stool consistency, as demonstrated by data from a pooled analysis of 15 studies comprising 1223 patients with IBS-D (32). Tricyclic antidepressants are also used off-label to treat symptoms of IBS-D, and a recent meta-analysis demonstrated that they may slow gut transit, improve global IBS symptoms and reduce pain (33). CAG guidelines recommend offering low-dose tricyclic antidepressants to improve IBS symptoms (19).

Antispasmodics are used off-label in the treatment of IBS based on the theory that smooth muscle spasms in the gut could contribute to IBS symptoms, particularly abdominal pain or cramps (29). A meta-analysis indicated that as a drug class, treatment with antispasmodics results in significant improvements in IBS symptoms with the number needed to treat of 5 (95% CI: 4 to 9); however, the effect of individual drugs is variable (29,30). In addition, the effects of individual agents are difficult to interpret given the small number of studies completed for the large number of available antispasmodics. Noting very low-quality evidence, CAG guidelines suggest offering certain antispasmodics (e.g., dicyclomine, hyoscine, pinaverium) to patients with IBS (19).

**Approved Prescription Therapies for IBS**

Recently, two new prescription therapies have entered the market for the treatment of IBS-D in Canada. Eluxadoline (Viberzi, Allergan, Parsippany, NJ/Markham, Ontario, Canada) is a novel µ- and κ-opioid receptor agonist and δ-opioid receptor antagonist administered orally twice daily at a dose of 100 mg (34–36). The CAG has made a conditional suggestion in favour of eluxadoline for the treatment of IBS-D symptoms (19).

Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, NJ/ ZAXINE, Lupin Pharma Canada, Montréal, Québec, Canada) is a minimally absorbed broad spectrum antibiotic derived from rifamycin administered orally three times daily at a dose of 550 mg for a total of 14 days (37,38). The recently updated CAG guidelines do not make a recommendation (either for or against) offering one course of rifaximin therapy to patients with IBS-D (19).

**Eluxadoline**

**Phase 2 and 3 Trials**

In a Phase 2 trial (NCT01130272), 807 patients meeting Rome III criteria for IBS-D were randomized to receive either placebo or eluxadoline 5, 25, 100 or 200 mg twice daily for 12 weeks (39). A significantly higher proportion of patients treated with eluxadoline 25 mg or 200 mg met the primary composite response criteria at Week 4 and Week 12 compared to placebo (Table 1). After 12 weeks, patients receiving eluxadoline 100 mg or 200 mg had greater improvements in bowel movement frequency, urgency, IBS global symptom scores, IBS severity scores, adequate relief and quality of life scores (39). As the U.S. Food and Drug Administration (FDA) released guidance on outcomes measures for IBS clinical trials after the initiation of this trial, a post-hoc analysis was also completed. A significantly greater proportion of patients in the eluxadoline 100 mg and 200 mg groups were FDA responders after 12 weeks of treatment compared to placebo, defined as ≥30% decrease in their daily worst abdominal pain score and a daily Bristol Stool Form Scale score of <5 or the absence of a bowel movement on ≥50% of days (39).

Two randomized, double-blind, placebo-controlled Phase 3 trials enrolled 2428 patients with IBS-D who met Rome III criteria (IBS-3001, NCT01553591 [26 weeks] and IBS-3002, NCT01553747 [26 weeks]) to receive placebo or eluxadoline 75 or 100 mg twice daily (40). The primary efficacy endpoint of both trials was the FDA composite response, consisting of a simultaneous improvement in both abdominal pain and stool consistency, evaluated at 12 and 26 weeks of treatment. Pooled data from the two clinical trials demonstrated that a significantly higher proportion of patients in the eluxadoline group were composite responders as compared to the placebo group (Figure 1A; Table 1). Improvements in symptoms, as assessed via the composite response, were evident within the first week of treatment in patients receiving eluxadoline and were maintained throughout the 26-week treatment period (Figure 1B) (40).

A significantly greater proportion of patients receiving either dose of eluxadoline were stool consistency responders at Week 12 (Table 1) (40). Eluxadoline was also effective in terms of number of urgency-free days, frequency, and bloating, with a significant reduction observed in these outcomes compared to placebo in the pooled analysis. A greater proportion of patients receiving eluxadoline were IBS global symptom responders and a significantly greater proportion of patients were adequate relief responders in both Phase 3 clinical trials (Table 1). Eluxadoline demonstrated effectiveness from the first week of
| Trial                          | Treatment (BID) | n    | Clinical responsea (patients, %) | ARb Week 4 | ARb Week 8 | ARb Week 12 |
|-------------------------------|-----------------|------|----------------------------------|------------|------------|------------|
|                               |                 |      | Week 4                           | Week 4     | Week 4     | Week 4     |
|                               |                 |      | Week 12                          | Week 12    | Week 12    | Week 12    |
| Phase 2 trial                 |                 |      |                                  |            |            |            |
| NCT01130272 (39)              | Placebo         | 159  | 5.7                              | 11.3       | 49.3       | 53.1       |
|                               | ELX 5 mg        | 105  | 12.4                             | 8.6        | 59.1       | 63.2       |
|                               | ELX 25 mg       | 167  | 12.0*                            | 13.2       | 62.4       | 64.2*      |
|                               | ELX 100 mg      | 163  | 11.0                             | 20.2*      | 69.3*      | 74.9*      |
|                               | ELX 200 mg      | 160  | 13.8*                            | 15.0       | 67.4       | 71.5*      |
|                               |                 |      |                                  |            |            |            |
|                               |                 |      |                                  |            |            |            |
| Phase 3 trial                 |                 |      |                                  |            |            |            |
| NCT01553591 (40)              | Placebo         | 427  | 17.1                             | 39.6       | 22.0       | 28.8       |
|                               | ELX 75 mg       | 426  | 23.9**                           | 42.4       | 30.0**     | 35.1       |
|                               | ELX 100 mg      | 427  | 25.1**                           | 43.2       | 34.3***    | 34.7       |
|                               |                 |      |                                  |            |            |            |
|                               |                 |      |                                  |            |            |            |
| IBS-3001                      |                 |      |                                  |            |            |            |
| Phase 3 trial                 | Placebo         | 381  | 16.2                             | 45.3       | 20.9       | 29.6       |
| NCT01553747 (40)              | ELX 75 mg       | 382  | 28.9***                          | 48.0       | 37.0***    | 43.6***    |
|                               | ELX 100 mg      | 382  | 29.6***                          | 51.0       | 35.6***    | 42.4***    |
|                               |                 |      |                                  |            |            |            |
|                               |                 |      |                                  |            |            |            |
| Pooled data (40)              | Placebo         | 808  | 16.7                             | –          | –          | –          |
|                               | ELX 75 mg       | 806  | 26.2***                          | –          | –          | –          |
|                               | ELX 100 mg      | 809  | 27.0***                          | –          | –          | –          |
|                               |                 |      |                                  |            |            |            |
|                               |                 |      |                                  |            |            |            |
| Post-hoc analysis             |                 |      |                                  |            |            |            |
| of IBS-3001                   | Placebo         | 809  | 12.5                             | 68.3       | 49.5       | 77.2       |
| and IBS-3002 (41)             | ELX 75 mg       | 808  | 22.8**                           | 72.8       | 63.0       | 81.5       |
|                               | ELX 100 mg      | 806  | 24.6**                           | 71.7       | 57.1       | 77.8       |
|                               |                 |      |                                  |            |            |            |
|                               |                 |      |                                  |            |            |            |
| Post-hoc analysis             |                 |      |                                  |            |            |            |
| of IBS-3001                   | Placebo         | 166  | 12.7                             | 25.0       | 17.5       | 26.7       |
| and IBS-3002 in patients who  | IS C (n = 166)  |      |                                  |            |            |            |
| reported prior loperamide use | ASC (n = 116)   |      |                                  |            |            |            |
| (42)                         | ELX 75 mg       | 198  | 26.3***                          | 37.5       | 26.8**     | 36.5       |
|                               | IS C (n = 198)  |      |                                  |            |            |            |
|                               | ASC (n = 96)    |      |                                  |            |            |            |
|                               | ELX 100 mg      | 122  | 27.0***                          | 41.8**     | 31.6**     | 44.3**     |
|                               | IS C (n = 174)  |      |                                  |            |            |            |
|                               | ASC (n = 116)   |      |                                  |            |            |            |
|                               |                 |      |                                  |            |            |            |
| Phase 4 trial                 |                 |      |                                  |            |            |            |
| NCT02959983 (43)              | Placebo         | 174  | 10.3                             | 31.0       | 16.7       |
|                               | ELX 100 mg      | 172  | 22.7**                           | 43.6*      | 27.9**     |
treatment; a post-hoc analysis indicated that an early clinical response to eluxadoline was shown to be associated with sustained response for up to 6 months (Table 1) (41).

In the two Phase 3 trials, 36.0% reported prior loperamide use (40) and of those, 61.8% reported inadequate symptom control (42). A post-hoc analysis assessed response to eluxadoline treatment in these patients (42); a greater proportion treated with eluxadoline were composite responders over 26 weeks as compared to those treated with placebo (Table 1). Efficacy was comparable irrespective of the use of loperamide as a rescue medication during the trial period (42).

Phase 4 Trial

The efficacy and safety of eluxadoline was evaluated in a Phase 4 trial (NCT02959983) in IBS-D patients who reported inadequate symptom control with prior loperamide (43). A significantly greater proportion of eluxadoline patients achieved the primary composite responder endpoint compared to placebo (22.7% vs 10.3%; P = 0.002), which was also reflected in the component endpoints (Table 1).

Safety

Eluxadoline was well tolerated in clinical trials. The most common adverse events (AEs) were constipation, abdominal pain and nausea (39,40,44) (Table 2). In the pooled Phase 2 and 3 trials, pancreatitis was the most commonly reported serious AE (SAE) among eluxadoline-treated patients; however, the overall incidence was low (0.4% of eluxadoline-treated patients). Ten events consistent with sphincter of Oddi spasm were reported in patients receiving eluxadoline, and seven events of pancreatitis were reported, all of which were defined as mild, and all patients discontinued treatment at event onset (44). No cases of sphincter of Oddi spasm or pancreatitis were reported in the Phase 4 trial (43). Eluxadoline is contraindicated in patients without a gallbladder, or patients who consume >3 alcoholic beverages a day, due to an increased risk of developing pancreatitis and/or sphincter of Oddi spasm (45,46). Patients should avoid excessive alcohol consumption while taking eluxadoline.

Eluxadoline has been reported to interact with cyclosporine, strong CYP inhibitors, and drugs that cause constipation (34,36). While eluxadoline is listed as a controlled substance due to its interaction with opioid receptors (34,36), a post-hoc analysis of Phase 2 and Phase 3 clinical trial data demonstrated a lack of abuse potential with eluxadoline treatment (47). The incidence of AEs potentially related to abuse (i.e., dizziness, fatigue, anxiety, etc.) was similar between the placebo, eluxadoline 75 mg, and eluxadoline 100 mg treatment groups, using the subjective opioid withdrawal scale, there was minimal evidence of withdrawal symptoms and no significant difference between the treatment groups in terms of withdrawal scores (47). Intranasal and oral eluxadoline abuse potential was also evaluated in healthy volunteers and demonstrated lower abuse potential than oxycodone (48).

Rifaximin

Phase 2 and 3 Trials

In a Phase 2 clinical trial (NCT00259155), 87 patients who met Rome I criteria for IBS were enrolled and randomized to receive rifaximin 400 mg three times daily or placebo for 10 days and were followed for 10 weeks post-treatment (49). Rifaximin resulted in greater improvements in IBS symptoms as compared to placebo over the 10 weeks of follow-up, with rifaximin-treated patients experiencing 36.4% improvement compared with 21.0% improvement in placebo-treated patients (P = 0.02) (49).
In two double-blind, placebo-controlled Phase 3 trials (NCT00731679, NCT00724126), 1260 patients with IBS without constipation were randomly assigned to rifaximin 550 mg or placebo three times daily for 2 weeks, and were followed for 10 subsequent weeks (50). The pooled data from the two studies demonstrated that significantly more patients in the rifaximin group had adequate relief of global IBS symptoms during the first 4 weeks following treatment than the placebo group, and maintained from 2 to 12 weeks post-treatment (Figure 2A and B). In addition, significantly more patients in the rifaximin group had adequate relief of bloating, achieved abdominal pain response and stool consistency response, and achieved the composite abdominal pain and stool consistency response than in the placebo group in the pooled analysis (Table 3) (50).

---

**Figure 1.** Eluxadoline efficacy in Phase 3 trials. Proportions of patients achieving composite response after 26 weeks of treatment in the Phase 3 clinical trials (individual trials and pooled data) after 26 weeks of treatment (A) and the proportion of composite responders over time in the pooled trials (B). *P < 0.05; **P < 0.001 vs. placebo. Defined as a ≥30% reduction from the average baseline score for worst abdominal pain on ≥50% of days and, on the same days, a stool consistency score of <5. If the patient did not have a bowel movement, an improvement of ≥30% in the worst abdominal pain score was sufficient for a response on that day. Figure 1A and B reproduced from Lembo et al. (40) in the New England Journal of Medicine by permission of Massachusetts Medical Society. Copyright ©2016 Massachusetts Medical Society.
In order to investigate the need for rifaximin re-treatment for long-term response, a randomized, placebo-controlled, 51-week Phase 3 trial (NCT01543178) enrolled patients with IBS without constipation (51). The trial consisted of a 2-week open-label treatment phase (rifaximin 500 mg three times daily) followed by a 4-week assessment phase, and efficacy was evaluated in 2438 patients. Patients who initially responded and subsequently experienced a relapse in IBS-D symptoms entered into the double-blind treatment phase. During the observation phase, 692 patients experienced a relapse; subsequently, 636 were randomized to

### Table 2. Safety overview of the eluxadoline clinical trials: pooled Phase 2 and Phase 3 data (44)

| AEs, n (%)          | Placebo BID, n = 975 | ELX 75 mg BID, n = 807 | ELX 100 mg BID, n = 1032 |
|---------------------|----------------------|------------------------|--------------------------|
| Patients with ≥1 AE| 533 (54.7)           | 486 (60.2)             | 575 (55.7)               |
| Events              | 1573                 | 1556                   | 1804                     |
| Patients with ≥1 SAE| 25 (2.6)             | 34 (4.2)               | 41 (4.0)                 |
| Events              | 28                   | 40                     | 65                       |
| Deaths              | 0                    | 0                      | 0                        |
| Patients with SOS   | 0                    | 2 (0.2)                | 8 (0.8)                  |
| Patients with pancreatitis<sup>b</sup> | 0               | 3 (0.4)                | 4 (0.4)                  |
| Any AE leading to discontinuation<sup>c</sup> | 42 (4.3)           | 67 (8.3)               | 80 (7.8)                 |
| Constipation        | 3 (0.3)              | 9 (1.1)                | 15 (1.5)                 |
| Abdominal pain      | 3 (0.3)              | 9 (1.1)                | 11 (1.1)                 |
| Nausea              | 4 (0.4)              | 5 (0.6)                | 0                        |
| Abdominal distension| 1 (0.1)              | 2 (0.2)                | 5 (0.5)                  |
| Abdominal pain upper| 0                    | 3 (0.4)                | 4 (0.4)                  |
| Pancreatitis<sup>d</sup> | 0                 | 3 (0.4)                | 3 (0.3)                  |
| Headache            | 1 (0.1)              | 3 (0.4)                | 1 (0.1)                  |
| Diarrhea            | 3 (0.3)              | 1 (0.1)                | 0                        |

AEs reported in ≥2% of any treatment group

- Constipation: 24 (2.5) Placebo, 60 (7.4) ELX 75 mg, 84 (8.1) ELX 100 mg
- Nausea: 49 (5.0) Placebo, 65 (8.1) ELX 75 mg, 73 (7.1) ELX 100 mg
- URTI: 38 (3.9) Placebo, 27 (3.3) ELX 75 mg, 53 (5.1) ELX 100 mg
- Abdominal pain: 25 (2.6) Placebo, 33 (4.1) ELX 75 mg, 47 (4.6) ELX 100 mg
- Headache: 44 (4.5) Placebo, 32 (4.0) ELX 75 mg, 44 (4.3) ELX 100 mg
- Vomiting: 12 (1.2) Placebo, 32 (4.0) ELX 75 mg, 43 (4.2) ELX 100 mg
- Dizziness: 21 (2.2) Placebo, 21 (2.6) ELX 75 mg, 33 (3.2) ELX 100 mg
- Flatulence: 17 (1.7) Placebo, 21 (2.6) ELX 75 mg, 33 (3.2) ELX 100 mg
- Nasopharyngitis: 33 (3.4) Placebo, 33 (4.1) ELX 75 mg, 31 (3.0) ELX 100 mg
- Bronchitis: 21 (2.2) Placebo, 26 (3.2) ELX 75 mg, 30 (2.9) ELX 100 mg
- Abdominal distension: 15 (1.5) Placebo, 21 (2.6) ELX 75 mg, 28 (2.7) ELX 100 mg
- Sinusitis: 35 (3.6) Placebo, 27 (3.3) ELX 75 mg, 27 (2.6) ELX 100 mg
- ALT increased: 14 (1.4) Placebo, 17 (2.1) ELX 75 mg, 26 (2.5) ELX 100 mg
- Fatigue: 23 (2.4) Placebo, 21 (2.6) ELX 75 mg, 20 (1.9) ELX 100 mg
- UTI: 17 (1.7) Placebo, 17 (2.1) ELX 75 mg, 18 (1.7) ELX 100 mg
- Gastroenteritis viral: 18 (1.8) Placebo, 22 (2.7) ELX 75 mg, 14 (1.4) ELX 100 mg
- Hypertension: 16 (1.6) Placebo, 20 (2.5) ELX 75 mg, 14 (1.4) ELX 100 mg

<sup>a</sup>ELX 75 mg was not evaluated in the Phase 2 trial. <sup>b</sup>Includes one event reported by the investigator as pancreatitis but adjudicated as not meeting Atlanta criteria for pancreatitis. <sup>c</sup>Occurring in ≥3 patients in any treatment group. <sup>d</sup>Includes all acute pancreatitis and pancreatitis events; one pancreatitis SAE was reported (ELX 100 mg group) but did not prompt discontinuation as the patient had been off trial drug for 2 weeks before event onset.

AE, adverse event; ALT, alanine aminotransferase; BID, twice daily; ELX, eluxadoline; SAE, serious adverse event; SOS, sphincter of Oddi spasm; URTI, upper respiratory tract infection; UTI, urinary tract infection.

Table 2 reproduced from Cash et al. (44). in Am J Gastroenterol. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318664/. Copyright ©2016 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode.
Figure 2. Rifaximin efficacy in Phase 3 trials. The proportion of patients achieving adequate relief of global IBS symptoms from Weeks 3 to 6 (A) and the proportion of patients achieving adequate relief of global IBS symptoms from the pooled trials over time (B). *P < 0.05; **P < 0.001 vs. placebo. Defined as a positive response to the question, ‘In regards to all your symptoms of IBS, as compared with the way you felt before you started the study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms?’ for ≥2 of the 4 weeks during Weeks 3–6. IBS, irritable bowel syndrome; TID, three times daily. Figure 2B reproduced from Pimentel et al. (50). in the New England Journal of Medicine by permission of Massachusetts Medical Society. Copyright ©2011 Massachusetts Medical Society.
| Trial      | Treatment (TID)  | weekly IBS-related bloating<sup>a</sup> | Daily global IBS symptoms<sup>b</sup> | Daily IBS-related bloating<sup>c</sup> | Daily abdominal pain and stool consistency<sup>d</sup> | Daily abdominal pain<sup>e</sup> | Daily stool consistency<sup>f</sup> |
|------------|-----------------|----------------------------------------|--------------------------------------|----------------------------------------|-----------------------------------------------------|-------------------------------|----------------------------------|
| TARGET 1   | Placebo         | 28.7                                   | 30.6                                 | 32.5                                   | 42.0                                                | 67.5                          |                                  |
| NCT00731679 (50) | Rifaximin 550 mg | 39.5*                                  | 42.7**                               | 39.2*                                  | 46.6*                                               | 51.5*                         | 79.0*                           |
| TARGET 2   | Placebo         | 31.9                                   | 28.4                                 | 30.9                                   | 36.3                                                | 43.1                          | 64.4                            |
| NCT00724126 (50) | Rifaximin 550 mg | 41.0*                                  | 37.8*                                | 43.5**                                 | 46.7*                                               | 52.4*                         | 74.0*                           |
| Pooled analysis (50) | Rifaximin 550 mg | 40.2**                                 | 40.2**                               | 41.3**                                 | 46.6**                                              | 51.9**                        | 76.4**                          |
| Trial      | Treatment (TID) | n                                      | CR<sup>g</sup>                       | Abdominal pain<sup>h</sup>            | Stool consistency<sup>i</sup>                       | Prevention of recurrence<sup>j</sup> | Durable response<sup>k</sup>     | Bloating<sup>l</sup>            |
| TARGET 3   | Placebo         | 308                                     | 31.5                                 | 42.2                                   | 50.0                                                | 7.1                           | 11.7                            | 41.2                            |
| NCT01543178 (51) | Rifaximin 550 mg | 328                                     | 38.1*                                | 50.6*                                  | 51.8                                                | 13.2*                         | 17.1*                           | 46.6                            |

<sup>a</sup> Defined as adequate relief in both abdominal pain and stool consistency during Weeks 1–4 following treatment, with no recurrence through the 6-week treatment-free repeat treatment observation phase and the second 6-week repeat treatment phase. Defined as adequate relief in both abdominal pain and stool consistency during Weeks 1–4 following treatment with no recurrence through the 6-week treatment-free repeat treatment observation phase. Defined as the percentage of patients with ≥1-point decrease (on a scale of 0–6, where 0 indicates not at all and 6 indicates a very great deal) from baseline in weekly average bloating score for ≥2 weeks during the 4-week primary evaluation period.

BSFS, Bristol Stool Form Scale; CR, composite response; IBS, irritable bowel syndrome; IBS-D, diarrhea-predominant irritable bowel syndrome; TID, three times daily.
double-blind repeat treatment. Patients were randomized to receive two repeat treatment courses of rifaximin 550 mg or placebo three times daily for 14 days, and were followed for 4 weeks after each treatment, with a treatment-free 6-week observation phase between the rounds of treatment. The percentage of responders during the double-blind treatment phase was significantly greater with rifaximin than with placebo (Table 3). The proportions of abdominal pain responders, prevention of recurrence responders, and durable response responders were also significantly greater with rifaximin treatment than with placebo (Table 3).

Safety
The AE rates observed during the clinical trials were low overall and were similar between the rifaximin and placebo groups (51). The most common AEs with rifaximin treatment included headache, upper respiratory tract infection and nausea (Table 4) (50,51). Incidences of drug-related AEs, SAEs, and infection-associated AEs were similar between the placebo and rifaximin groups in the pooled Phase 2 and Phase 3 clinical trial data (52). The incidence and types of AEs were similar with repeat rifaximin treatment (51). Rifaximin demonstrates very minimal drug–drug interactions, and is only known to interact significantly with cyclosporine (37,38).

Antibiotic Resistance Considerations
Rifaximin is administered orally three times daily at a dose of 550 mg for a total of 14 days, with up to two re-treatments for patients who experience symptom recurrences (37,38). In the Phase 2 and Phase 3 clinical trials, the effect of rifaximin seemed to decrease over time (Figure 2B), and patients experienced a relapse in occurrence of IBS symptoms, resulting in administration of repeat courses of rifaximin (51,53). Despite the concerns surrounding repeat treatment with antibiotics, short-term rifaximin treatment has not shown any association with clinically relevant antibiotic resistance (53). In post-hoc analyses of Phase 3 trials, it was demonstrated that Clostridium difficile was highly susceptible to rifaximin. In addition, rifaximin exposure was not associated with long-term cross resistance to rifampin or tested nonrifamycin antibiotics (53).

While data indicate that rifaximin is effective in patients with IBS-D and mixed IBS, the mechanism of action for its benefits is largely unknown and warrants further investigation (54). Although short courses of rifaximin have been shown not to result in antibiotic resistance, rifamycins are important for the treatment of serious infections, and the use of an antibiotic to treat a common disorder without understanding its mechanism of action raises a concern (53). With data showing that the durability of the effect of rifaximin decreases over time, the possibility of multiple re-treatments with an antibiotic that has a diminishing effect raises further concerns regarding antibiotic resistance (51).

Conclusions
IBS is a prevalent gastrointestinal disorder, which significantly impacts patients’ quality of life. Presentation of patients with IBS is common in gastroenterology clinics and practices, and physicians need to be aware that safe and effective treatments exist and can help their patients. The heterogeneous presentation and multifactorial pathogenesis of IBS-D require an individualized approach to the management of IBS-D symptoms. Eluxadoline and rifaximin are two novel treatments for adults with IBS-D that show promising efficacy and safety for this disorder with a high burden of illness. Real-world studies are warranted to provide information on which patients would most benefit from various treatment regimens.

### Table 4. Safety overview of the rifaximin clinical trials

| AE, n (%) | Placebo n = 829 | All pooled rifaximin n = 1103 |
|-----------|-----------------|-------------------------------|
| Any AE    | 436 (52.6)      | 579 (52.5)                    |
| Specific AE in ≥2% of patients<sup>a</sup> |                   |                               |
| Headache  | 51 (6.2)        | 59 (5.3)                      |
| URTI      | 47 (5.7)        | 50 (4.5)                      |
| Nausea    | 31 (3.7)        | 48 (4.4)                      |
| Abdominal pain | 39 (4.7) | 41 (3.7)                      |
| Diarrhea  | 26 (3.1)        | 37 (3.4)                      |
| UTI       | 18 (2.2)        | 37 (3.4)                      |
| Nasopharyngitis | 39 (4.7) | 26 (2.4)                      |
| Sinusitis | 23 (2.8)        | 24 (2.2)                      |
| Vomiting  | 12 (1.4)        | 22 (2.0)                      |
| Back pain | 19 (2.3)        | 22 (2.0)                      |
| AE severity<sup>b</sup> |                   |                               |
| Mild      | 169 (20.4)      | 268 (24.3)                    |
| Moderate  | 214 (25.8)      | 246 (22.3)                    |
| Severe    | 53 (6.4)        | 63 (5.7)                      |
| Drug-related AEs | 89 (10.7) | 134 (12.1)                    |
| SAEs      |                 |                               |
| Any SAE   | 18 (2.2)        | 16 (1.5)                      |
| Drug-related SAE | 2 (0.2) | 1 (0.1)                       |
| Deaths    | 0               | 0                             |
| AEs resulting in study discontinuation |                   |                               |
| Any AE    | 14 (1.7)        | 22 (2.0)                      |
| Drug-related AE | 7 (0.8) | 9 (0.8)                       |

Adapted from Schoenfeld et al (52). in *Alimentary Pharmacology & Therapeutics*, by permission of John Wiley & Sons Ltd. Copyright ©2014 The Authors.

<sup>a</sup>Occurring in ≥2% of patients in either rifaximin group or in the placebo group. <sup>b</sup>Data not available for two AEs in the rifaximin group.

AE, adverse event; SAE, serious adverse event; URTI, upper respiratory tract infection; UTI, urinary tract infection.
Acknowledgments

Disclosures: The authors would like to thank Katie L. Beski, PhD, of Complete HealthVizion, Inc., Chicago, IL, USA for writing and editorial assistance in the writing and revision of the draft manuscript on the basis of detailed discussion and feedback from all the authors; this assistance was funded by Allergan plc, Dublin, Ireland.

Author Contributions: The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors. C.N.A. and M.B. provided the scope, direction, and content of the manuscript and have approved the submitted manuscript. The authors received no compensation related to the development of the manuscript.

Conflicts of Interest: Financial arrangements of the authors with companies whose products may be related to the present report are listed below, as declared by the authors. C.N.A. has received research funding from Allergan and Janssen, and honoraria from Allergan, Lupin Pharmaceuticals, PendoPharm and AbbVie. M.B. has been involved in advisory boards and has been a speaker for Allergan, Lupin Pharmaceuticals, AbbVie, Janssen, Takoda, Gilead, Pfizer, Shire and Merck.

References

1. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clin Gastroenterol Hepatol 2012;10(7):171–21.e4.
2. Fedorak RN, Vanner SJ, Paterson WG, et al. Canadian Digestive Health Foundation Public Impact Series: Irritable bowel syndrome in Canada. Incidence, prevalence, and direct and indirect economic impact. Can J Gastroenterol 2012;26(5):252–6.
3. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol 2014;6:71–80.
4. Lacy BE, Meairn F, Chang L, et al. Bowel disorders. Gastroenterology 2016;150:1393–407.
5. Dressman DA. Functional gastrointestinal disorders: History, pathophysiology, clinical features, and Rome IV. Gastroenterology 2016;150:1262–79.e2.
6. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: A clinical review. JAMA 2015;313(9):949–58.
7. El-Serag HB, Pilgrim P, Schoenfeld P. Systemic review: Natural history of irritable bowel syndrome. Aliment Pharmacol Ther 2004;19(8):861–70.
8. Brenner DM, Dove LS, Andrae DA, et al. Using radar plots to display disparate global health care resource utilization of subjects with irritable bowel syndrome: Baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther 2006;28(10):1726–35; discussion 1710–1.
9. Paré P, Gray J, Lam S, et al. Health-related quality of life, work productivity, and health care resource utilization of patients with irritable bowel syndrome: Results from the Canadian IBS quality-of-life study. Aliment Pharmacol Ther 2005;21(11):1365–75.
10. Paré P, Gray J, Lam S, et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: Baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther 2006;28(10):1726–35; discussion 1710–1.
11. Ballou S, Bedell A, Keefer L. Psychosocial impact of irritable bowel syndrome: A brief review. World J Gastrointest Pathophysiol 2015;6(4):120–3.
12. Laxton C, Scarpignato C. Systematic review with meta-analysis: Rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 2017;45(5):604–16.
13. Ford AC, Spiegel BM, Talley NJ, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: Systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009;7(12):1279–86.
14. Rezaie A, Buresi M, Lembo A, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American Consensus. Am J Gastroenterol 2017;112(5):775–84.
15. Vanner S. The lactulose breath test for diagnosing SIBO in IBS patients: Another nail in the coffin. Am J Gastroenterol 2008;103(4):964–5.
16. Moayyedi P, Andrews CN, MacQueen G, et al. Canadian Association of Gastroenterology clinical practice guideline for the management of irritable bowel syndrome (IBS). Can Assoc Gastroenterol 2019;2(1):6–29.
17. Lucka S, Chang L, Halpert A, et al. Current and emerging pharmacologic treatments for irritable bowel syndrome with diarrhea: Evidence-based treatment in practice. Therap Adv Gastroenterol 2017;10(2):253–75.
18. Bohn L, Störrs M, Törnbom H, et al. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am J Gastroenterol 2013;108(5):634–41.
19. Ballou S, Keefer L. Psychological interventions for irritable bowel syndrome and inflammatory bowel diseases. Clin Transl Gastroenterol 2017;8(1):e21–4.
20. Altyar O, Sharma V, Prekop LJ, et al. Psychological therapies in patients with irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials. Gastroenterol Res Pract 2015;2015:949:08.
21. Vanner S. The lactulose breath test for diagnosing SIBO in IBS patients: Another nail in the coffin. Am J Gastroenterol 2008;103(4):964–5.
22. Lucak S, Chang L, Halpert A, et al. Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014;109(Suppl 1):S2–26; quiz S27.
23. Lucak S, Moayyedi P, Chey WD et al.; ACG Task Force on Management of Irritable Bowel Syndrome. American college of gastroenterology monograph on management of Irritable Bowel Syndrome. Am J Gastroenterol 2018;113(Suppl 2):1–18.
24. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: Systematic review and meta-analysis. Am J Gastroenterol 2014;109(10):1547–61; quiz 1546, 1562.
25. Wedlake L, A’Hern R, Russell D, et al. Systematic review: The prevalence of idiopathic bile acid malabsorption as diagnosed by seHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2009;30(7):707–17.
26. Ford AC, Quigley EM, Lacy BE, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome. Systematic review and meta-analysis. Am J Gastroenterol 2014;109(9):1350–65; quiz 1366.
27. Allergan plc. Viberzi product monograph – Canada. 2017. Available from: https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actsavis-canada-specialty/en/products/pms/2017-01-26-viberzi-pm-english.pdf. Accessed February 14, 2018.
28. European Medicines Agency. Truberis Assessment Report. 2016. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR___Public_assessment_report/human/004098/WC500213370.pdf. Accessed February 14, 2018.
29. US Food and Drug Administration. Viberzi. Highlights of prescribing information. 2018. Available from: https://www.allergan.com/assets/pdf/pdfs/viberzi_pi. Accessed November 8, 2018.
30. US Food and Drug Administration. Xifaxan (rifaximin) Highlights of Prescribing Information. 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201361s023lbl.pdf. Accessed April 10, 2019.
31. Lupin Pharma Canada. Xifaxan (Rifaximin) Product Monograph. 2019. Available from: https://www.lupinpharma.ca/docs/pdf_pdm_200000315P.pdf. Accessed April 10, 2019.
32. Ford DS, Lembo A, Randall CW, et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology 2013;145(2):329–38.e1.
33. Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med 2016;374(3):342–53.
34. Chey WD, Ford DS, Andrae DA, et al. Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhea in two Phase 3 studies. Aliment Pharmacol Ther 2017;45(10):1319–28.
35. Lacy BE, Chey WD, Cash BD, et al. Eluxadoline efficacy in IBS-D patients who report prior loperamide use. Am J Gastroenterol 2017;112(6):924–32.
36. Brenner DM, Gutman C, Je E. Efficacy and safety of eluxadoline in IBS-D patients who report inadequate symptom control with prior loperamide use: A Phase 4,
multicenter, multinational, randomized, placebo-controlled, double-blinded study (RELIEF). Poster P0344 presented at the American College of Gastroenterology Annual Scientific Meeting, Philadelphia, PA, USA, October 5–10, 2018.

44. Cash BD, Lacy BE, Schoenfeld PS, et al. Safety of eluxadoline in patients with irritable bowel syndrome with diarrhea. Am J Gastroenterol 2017;112(2):365–74.

45. Afghani E, Lo SK, Covington PS, et al. Sphincter of Oddi function and risk factors for dysfunction. Front Nutr 2017;4:1.

46. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder. 2017. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm546154.htm. Accessed August 6, 2018.

47. Fant RV, Henningfield JE, Cash BD, et al. Eluxadoline demonstrates a lack of abuse potential in phase 2 and 3 studies of patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol 2017;15(7):1021–9.e6.

48. Levy-Cooperman N, McIntyre G, Bonifacio L, et al. Lack of subjective abuse-related effects of oral eluxadoline: A novel mu-delta opiate modulator for oral use in IBS-D. Poster PH-020 presented at the Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, San Diego, CA, USA, March 8–12, 2016.

49. Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: A randomized trial. Ann Intern Med 2006;145(8):557–63.

50. Pimentel M, Lembo A, Chey WD, et al.; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364(1):22–32.

51. Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology 2016;151(6):1113–21.

52. Schoenfeld P, Pimentel M, Chang L, et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: A pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2014;39(10):1161–8.

53. Pimentel M, Cash BD, Lembo A, et al. Repeat rifaximin for irritable bowel syndrome: No clinically significant changes in stool microbial antibiotic sensitivity. Dig Dis Sci 2017;62(9):2455–63.

54. Acosta A, Camilleri M, Shin A, et al. Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome. Clin Transl Gastroenterol 2016;7:e173.